RETA (Retatrutide) is an investigational triple‑agonist medication designed to activate GLP‑1, GIP, and glucagon receptors. This multi‑pathway approach aims to improve metabolic regulation more powerfully than single‑ or dual‑agonist drugs.

Key information and effects:

Retatrutide has shown significant weight‑loss potential in clinical trials, producing greater reductions in body weight than current GLP‑1‑only medications.

By activating GLP‑1 and GIP receptors, it enhances insulin secretion, reduces appetite, slows gastric emptying, and improves blood glucose control.

Activation of the glucagon receptor increases energy expenditure and may help reduce liver fat.

Early studies indicate benefits for people with obesity, type 2 diabetes, and metabolic‑associated fatty liver disease.

Participants in trials have seen improvements in cholesterol, inflammation markers, and overall metabolic health.